Nature Communications (Jun 2019)
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
- Min Thura,
- Abdul Qader Al-Aidaroos,
- Abhishek Gupta,
- Cheng Ean Chee,
- Soo Chin Lee,
- Kam Man Hui,
- Jie Li,
- Yeoh Khay Guan,
- Wei Peng Yong,
- Jimmy So,
- Wee Joo Chng,
- Chin Hin Ng,
- Jianbiao Zhou,
- Ling Zhi Wang,
- John Shyi Peng Yuen,
- Henry Sun Sien Ho,
- Sim Mei Yi,
- Edmund Chiong,
- Su Pin Choo,
- Joanne Ngeow,
- Matthew Chau Hsien Ng,
- Clarinda Chua,
- Eugene Shen Ann Yeo,
- Iain Bee Huat Tan,
- Joel Xuan En Sng,
- Nicholas Yan Zhi Tan,
- Jean Paul Thiery,
- Boon Cher Goh,
- Qi Zeng
Affiliations
- Min Thura
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Abdul Qader Al-Aidaroos
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Abhishek Gupta
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Cheng Ean Chee
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Soo Chin Lee
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Kam Man Hui
- Division of Cellular and Molecular Research, National Cancer Centre Singapore
- Jie Li
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Yeoh Khay Guan
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
- Wei Peng Yong
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Jimmy So
- Division of Surgical Oncology, National University Cancer Institute, Singapore (NCIS)
- Wee Joo Chng
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Chin Hin Ng
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Jianbiao Zhou
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Ling Zhi Wang
- Cancer Science Institute of Singapore, National University of Singapore
- John Shyi Peng Yuen
- Department of Urology, Singapore General Hospital
- Henry Sun Sien Ho
- Department of Urology, Singapore General Hospital
- Sim Mei Yi
- Department of Urology, Singapore General Hospital
- Edmund Chiong
- Division of Surgical Oncology, National University Cancer Institute, Singapore (NCIS)
- Su Pin Choo
- Division of Medical Oncology, National Cancer Centre Singapore
- Joanne Ngeow
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Matthew Chau Hsien Ng
- Division of Medical Oncology, National Cancer Centre Singapore
- Clarinda Chua
- Division of Medical Oncology, National Cancer Centre Singapore
- Eugene Shen Ann Yeo
- Department of Colorectal Surgery, Singapore General Hospital
- Iain Bee Huat Tan
- Division of Medical Oncology, National Cancer Centre Singapore
- Joel Xuan En Sng
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Nicholas Yan Zhi Tan
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Jean Paul Thiery
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Boon Cher Goh
- Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
- Qi Zeng
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- DOI
- https://doi.org/10.1038/s41467-019-10127-x
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Phosphatase of regenerating liver 3 (PRL3) is usually found intracellularly, and is over-expressed in cancer cells. Here the authors show that PRL-3 is also detectable on cell surface, and can be recognized by PRL3-zumab to recruit immune cells into tumor to promote anti-tumor immunity, thereby implicating PRL-3 as a potential tumor antigen.
